Safety and Efficacy Study to Compare Two Rosacea Treatment Regimens
NCT ID: NCT00495313
Last Updated: 2008-12-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
91 participants
INTERVENTIONAL
2007-03-31
2007-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: doxycycline
Vibramycin plus metronidazole
doxycycline
COL-101, QD plus metronidazole
Cohort 2
Oracea® delayed release plus metronidazole
doxycycline
40 mg with metronidazole QD
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
doxycycline
COL-101, QD plus metronidazole
doxycycline
40 mg with metronidazole QD
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* erythema
* telangiectasia
Exclusion Criteria
* achlorhydric
* gastric by-pass surgery
* allergy to study medications
* drug/alcohol abuse
* use of proton pump inhibitors
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CollaGenex Pharmaceuticals
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
CollaGenex Pharmaceuticals
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Christopher V Powala, JD
Role: STUDY_CHAIR
CollaGenex Pharmaceuticals
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Joel Schlessinger
Omaha, Nebraska, United States
James Del Rosso
Las Vegas, Nevada, United States
Angela Moore
Arlington, Texas, United States
William Abramovits
Dallas, Texas, United States
Douglas Forsha
West Jordan, Utah, United States
Bernard Goffe
Seattle, Washington, United States
William Werschler
Spokane, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COL101-ROSE-401
Identifier Type: -
Identifier Source: org_study_id